Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04759339 · ClinicalTrials.gov registry record · Phase 1
An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920
A Phase 1 study, sponsored by American Genomics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04759339: Completed Phase 1 study, sponsored by American Genomics.
NCT04759339 is a Phase 1 study that has completed, run by American Genomics. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04759339, a Phase 1 study, has completed, sponsored by American Genomics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US. It is designed to assess systemic exposure to articaine and its metabolite articainic acid after dosing a single topical ocular administration of AG-920 in the randomized study eye.
Primary Outcome
Plasma levels of articaine and its primary metabolite (articainic acid)
Interventions
- DRUG AG-920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2021-02-25 |
| Phase | Phase 1 |
What the finished NCT04759339 record still lists
NCT04759339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which AG-920 is the first listed.
NCT04759339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04759339 about?
NCT04759339 is a clinical study titled "An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920". This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US. It is designed to assess systemic exposure to articaine and its metabolite articainic acid after dosing a single topical ocular administration of AG-920 in the randomized study eye.
What is the current status of trial NCT04759339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-02-24. Estimated completion is 2021-02-25.
What interventions are being tested in trial NCT04759339?
The interventions under investigation include: AG-920 (DRUG).
Who is sponsoring clinical trial NCT04759339?
This trial is sponsored by American Genomics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04759339's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy